Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite BioPharma completed enrolment of 247 patients for the interim analysis of its pivotal Phase 3 study evaluating Piclidenoson for moderate-to-severe plaque psoriasis. The interim analysis is conducted under a protocol agreed with the FDA and EMA, with data expected in Q4 2026 or Q1 2027.
Key figures
- Drug Name
- Piclidenoson
- Phase Of Trial
- Phase 3
- Pasi target
- ≥75%
- Spga target
- 0 or 1
- Patients enrolled interim
- 247
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.